Bilmez Tan, RumeysaTekin, SerekAkman Ilik, ZehraBatur, MuhammedSeven, ErbilTan Uygun, Meltem2026-01-302026-01-3020260271-36831460-220210.1080/02713683.2025.26021672-s2.0-105026735411https://doi.org/10.1080/02713683.2025.2602167https://hdl.handle.net/20.500.14720/29642Tan-Uygun, Meltem/0000-0003-4190-6047Purpose: To evaluate the therapeutic effects of bakuchiol on clinical and histopathological outcomes in a rat model of corneal alkali burn.MethodsCorneal alkali burns were induced in the right eyes of 35 male Wistar rats, which were randomized into five groups: control, carbomer, steroid, 0.14 mg/g bakuchiol, and 0.28 mg/g bakuchiol. Examinations were performed under stereomicroscopy with intraperitoneal ketamine anesthesia on days 0, 3, 7, and 14 to assess corneal epithelial defects and opacity; on day 14, corneal neovascularization was additionally evaluated. After the final examination, the eyes were enucleated, and the corneas were processed for hematoxylin-eosin and immunohistochemical staining. Epithelial necrosis, inflammatory cell density, corneal hemorrhage, stromal edema, and staining intensity for VEGF and TNF-alpha were semi-quantitatively scored.ResultsBakuchiol treatment, particularly at 0.28 mg/g, significantly reduced corneal opacity, neovascularization, hemorrhage, and stromal edema compared with the steroid-treated group.ConclusionsBakuchiol demonstrated promising anti-inflammatory and anti-angiogenic effects and may represent a potential adjunctive treatment for corneal chemical injuries.eninfo:eu-repo/semantics/closedAccessBakuchiolCorneal Alkali InjuryVEGFTNF-AlphaHydrogel1Article